Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2013 Oct 31;41(2):322–332. doi: 10.1007/s00259-013-2558-9

Table 2.

Specific activity estimates, logD, IC50, and serum protein binding data, and doses used for various studies.

[18F]MFBG [18F]PFBG 123I-MIBG [124I]MIBG
Structure graphic file with name nihms536584t1.jpg graphic file with name nihms536584t2.jpg graphic file with name nihms536584t3.jpg graphic file with name nihms536584t4.jpg
Specific activity (GBq/µmol) 18.7±1.1 (n = 3) >18 ~0.31 > 12
LogD (1-Octanol/PBS) −0.52±0.01 (n = 2) −0.48±0.01 (n = 2) 0.42±0.01 (n = 3)
IC50(µM) 4.9±0.6 (n = 4) 9.8±2.5 (n = 2) 1.7±0.6 (n = 4)
% unbound to human serum protein 69.5±3.3 (n = 2) NT 12.4±0.5 (n = 2)
% unbound to mouse serum protein 66.9±1.1 (n = 2) NT 29.2±2.0 (n = 2)
Dose for in vitro cell uptake (kBq/well) 11.1 11.1 3.7 3.7
Dose for in vivo image (MBq/mouse) 5.5±1.8 (n = 7) 7.4±1.8 (n = 5) NT 5.1 (n = 5)
Dose for biodistribution (MBq/mouse) 5.9 NT 2.8 5.1

The number of independent studies is given in parentheses; with triplicates in each experiment. NT, not tested.